Effectiveness of Intra-Arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma: Relevance of a Multidisciplinary Setting

Purpose We aim to report about effectiveness and safety in the context of our centers’ setting in the management of retinoblastoma with intra-arterial chemotherapy (IAC) in a 5-year retrospective analysis of the Portuguese population. Patients and Methods Retrospective analysis of consecutive cases of retinoblastoma selected to initiate IAC between 2015 and 2020, at the Portuguese National Reference Center. All included patients underwent complete ophthalmological evaluation under anesthesia with fundus photography. Diagnosis and classification of retinoblastoma was made according to the International Classification of Intraocular Retinoblastoma (ICRB). The patients were further divided into two groups: Group I for primary IAC and Group II for secondary IAC. Tumor recurrence or relapses, systemic metastasis and deaths were documented. Main efficacy outcome included ocular salvage and recurrence-free survival rates estimated using the Kaplan–Meier method. Results Twenty-eight eyes (19 eyes included in Group I and 9 eyes included in Group II) were eligible and a total of 130 IAC procedures were performed, with a median number of sessions of 4 (range 1–8) for each treated eye, during a median follow-up of 21 months (range 4–64). Of the included eyes, 22 (78.6%) were preserved. An overall survival of 100% was achieved. Considering the preserved eyes, the overall median decimal visual acuity achieved at the last visit was 0.15 (range 0.02–0.8). Three patients had permanent adverse events related to IAC (cataract, vitreous hemorrhage and choroidal ischemia). Considering the survival analysis of recurrence, the mean survival without recurrence was 84.2% for Group I and 66.7% for Group II, and the mean survival without enucleation was 78.6% (no events in Group II). Conclusion IAC has been shown to be an effective and safe treatment for children with intraocular retinoblastoma. This study demonstrates that IAC is effective even in moderate sample sizes, when a multidisciplinary approach is available.

[1]  Peiquan Zhao,et al.  Outcome of salvage intra-arterial chemotherapy for recurrent retinoblastoma , 2021, Eye.

[2]  Funda Seher Özalp Ateş,et al.  Recurrence and new tumor development after frontline intravenous chemotherapy for retinoblastoma: Risk factors and treatment results , 2021, European journal of ophthalmology.

[3]  C. Shields,et al.  Intra-arterial chemotherapy for retinoblastoma in 341 consecutive eyes (1,292 infusions): comparative analysis of outcomes based on patient age, race, and sex. , 2021, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[4]  K. Yavuz,et al.  Secondary intra-arterial chemotherapy and/or intravitreal chemotherapy as salvage treatment for retinoblastoma , 2020, European journal of ophthalmology.

[5]  Bin Zhang,et al.  Intra-arterial chemotherapy as primary or secondary treatment for infants diagnosed with advanced retinoblastoma before 3 months of age , 2019, BMC Cancer.

[6]  C. Shields,et al.  Intra-arterial chemotherapy in retinoblastoma – A paradigm change , 2019, Indian journal of ophthalmology.

[7]  J. Pulido,et al.  Intra-arterial chemotherapy for retinoblastoma: an updated systematic review and meta-analysis , 2019, Journal of NeuroInterventional Surgery.

[8]  G. Abbott Detachment , 2018, Thucydides.

[9]  S. Brodie,et al.  Current Treatment of Bilateral Retinoblastoma: The Impact of Intraarterial and Intravitreous Chemotherapy , 2018, Neoplasia.

[10]  E. Zabor,et al.  Ten-year experience with ophthalmic artery chemosurgery: Ocular and recurrence-free survival , 2018, PloS one.

[11]  C. Shields,et al.  Secondary and tertiary intra-arterial chemotherapy for massive persistent or recurrent subretinal retinoblastoma seeds following previous chemotherapy exposure: long-term tumor control and globe salvage in 30 eyes. , 2016, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[12]  S. Brodie,et al.  Simultaneous Bilateral Ophthalmic Artery Chemosurgery for Bilateral Retinoblastoma (Tandem Therapy) , 2016, PloS one.

[13]  J. Augsburger,et al.  Selective Ophthalmic Artery Infusion Chemotherapy for Advanced Intraocular Retinoblastoma: CCHMC Early Experience , 2016, Journal of pediatric hematology/oncology.

[14]  T. S. Balbuena,et al.  Quantitative proteomic analysis of Araucaria angustifolia (Bertol.) Kuntze cell lines with contrasting embryogenic potential. , 2016, Journal of proteomics.

[15]  A. Fabius,et al.  Advanced Unilateral Retinoblastoma: The Impact of Ophthalmic Artery Chemosurgery on Enucleation Rate and Patient Survival at MSKCC , 2015, PloS one.

[16]  C. Shields,et al.  Treatment of Retinoblastoma in 2015: Agreement and Disagreement. , 2015, JAMA ophthalmology.

[17]  J. Augsburger,et al.  Adjunctive techniques for optimization of ocular hemodynamics in children undergoing ophthalmic artery infusion chemotherapy , 2014, Journal of NeuroInterventional Surgery.

[18]  S. Hetts,et al.  Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: results from a single institution , 2013, Clinical ophthalmology.

[19]  S. Brodie,et al.  Combined, Sequential Intravenous and Intra-Arterial Chemotherapy (Bridge Chemotherapy) for Young Infants with Retinoblastoma , 2012, PloS one.

[20]  S. Brodie,et al.  Success of intra-arterial chemotherapy (chemosurgery) for retinoblastoma: effect of orbitovascular anatomy. , 2012, Archives of ophthalmology.

[21]  C. Shields,et al.  Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. , 2011, Archives of ophthalmology.

[22]  S. Brodie,et al.  Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results , 2011, British Journal of Ophthalmology.

[23]  S. Brodie,et al.  Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. , 2011, Archives of ophthalmology.

[24]  E. Peterson,et al.  Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors. , 2011, Journal of neurosurgery.

[25]  S. Brodie,et al.  Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). , 2010, Ophthalmology.

[26]  A. Berrocal,et al.  SUPRASELECTIVE INJECTION OF INTRAARTERIAL MELPHALAN AS THE PRIMARY TREATMENT FOR LATE PRESENTATION UNILATERAL MULTIFOCAL STAGE VB RETINOBLASTOMA , 2010, Retina.

[27]  S. Brodie,et al.  Bilateral superselective ophthalmic artery chemotherapy for bilateral retinoblastoma: tandem therapy. , 2010, Archives of ophthalmology.

[28]  S. Brodie,et al.  A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. , 2008, Ophthalmology.

[29]  D. Rhee,et al.  Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. , 2006, Current opinion in ophthalmology.

[30]  T. Kivelä,et al.  Incidence of retinoblastoma from 1958 to 1998 in Northern Europe: advantages of birth cohort analysis. , 2004, Ophthalmology.

[31]  A. Kaneko,et al.  The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma , 2004, International Journal of Clinical Oncology.